Drug Trial Radar · NCT07575984
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 4, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- PharmasoftIndustry
- Sponsor type
- Industry
- First posted
- May 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.
Conditions
- Ischemic Stroke
Interventions
MexidolDrug
Phase 1 (Days 1-10): Mexidol® solution, 500 mg (10 ml) twice daily (total daily dose 1000 mg) administered via IV infusion in 100-200 ml of 0.9% NaCl solution for 10 days. Infusion rate: 40-60 drops per minute. Phase 2 (Days 11-70): Mexidol® FORTE 250 film-coated tablets, 250 mg three times daily (total daily dose 750 mg) for 60 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.
GlycineDrug
Glycine, 100 mg sublingual tablets, 1 g (10 tablets) daily for 5 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Infarct Volume at Visit 2 (Day 11)Time frame: Day 11 (Visit 2).
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
First City Clinical Hospital named after E.E. Volosevich
Arkhangelsk, Russia · Recruiting
Ivanovo Regional Clinical Hospital
Ivanovo, Russia · Recruiting
Regional Clinical Hospital
Ryazan, Russia · Recruiting
Hospital for War Veterans
Saint Petersburg, Russia · Recruiting
City Hospital № 40 of Kurortny District
Saint Petersburg, Russia · Recruiting
Smolensk Regional Clinical Hospital
Smolensk, Russia · Recruiting
Regional Clinical Hospital
Tver', Russia · Recruiting
Regional Clinical Hospital
Yaroslavl, Russia · Recruiting
Zhukovskiy Regional Clinical Hospital,
Zhukovskiy, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.